ReviewPrecision chemistry2025
Tumor Extracellular Vesicle Digital Scoring Assays for Cancer Detection and Monitoring.
Review in Precision chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- ResNet-KAN for Small-Sample Chemical Formulation Prediction: Hybrid Architecture and Interpretability Analysis.Precision chemistry · 2026Article
- Bioorthogonal Click Chemistry-Enabled Enrichment of Extracellular Vesicles for Integrated Molecular and Functional Liquid Biopsy§.Accounts of chemical research · 2026Article
- Precision Chemistry in Precision Diagnostics.Precision chemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Tumor-derived extracellular vesicles (EVs) have emerged as promising targets for liquid biopsy, enabling noninvasive mRNA profiling to support cancer detection, staging, and treatment monitoring. This Review highlights the development and clinical translation of EV Digital Scoring Assays, an innovative class of two-step liquid biopsy platforms integrating click chemistry-mediated tumor EV enrichment (via EV Click Beads or EV Click Chips) with reverse transcription digital PCR (RT-dPCR) for absolute quantification of tumor mRNA. These assays have demonstrated clinical utility across multiple solid tumors: identifying oncogenic alterations in pancreatic ductal adenocarcinoma and Ewing sarcoma, detecting early stage hepatocellular carcinoma in at-risk cirrhotic patients, differentiating localized from metastatic prostate cancer, and monitoring treatment response in hepatocellular carcinoma. We also examine emerging technologies and parallel efforts from other groups, including microfluidic isolation platforms, PCR-free digital detection, and machine learning-based analytics. Together, these studies showcase how "enrich-then-count" strategies can overcome challenges in tumor EV specificity and transcript quantification, offering scalable solutions for precision oncology. The EV Digital Scoring Assay provides a versatile and modular platform, potentially enabling broad adoption across diverse tumor types and clinical contexts for real-time noninvasive cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.